Potential therapy for most aggressive type of lung cancer in preclinical models
Thursday, February 11, 2016 - 16:10
in Health & Medicine
The specific combination of the drugs dasatinib and demcizumab impairs the growth of KRAS-driven lung tumors, the most aggressive sub-type and with the lowest survival rates. The research was conducted on mouse models and samples of human tumors. The experts are confident they can soon start clinical trials which will make it possible to transfer the discoveries to cancer patients.